SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions ...
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis The Afirma XA uses RNA whole-transcriptome sequencing to detect expressed DNA variants and RNA ...
Company launches expanded content to detect novel NTRK, ALK, RET and BRAF fusions at time of diagnosis The new data are featured in an abstract that was accepted for an oral presentation this week at ...
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
Using 943 blinded FNA samples, they found the Afirma XA had high positive predictive agreement (PPA) with targeted DNA sequencing (88 percent) and targeted RNA sequencing (89 percent). Similarly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results